Related Experiment Video
Updated: Jun 18, 2026
05:46
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Drug-drug interactions with raltegravir
1Department of Clinical Pharmacy, 864 Radboud University Nijmegen Medical Centre, Geert Grooteplein 10, 6525 GA Nijmegen, The Netherlands. D.Burger@akf.umcn.nl
European Journal of Medical Research
|December 5, 2009
Summary
Raltegravir, an HIV-integrase inhibitor, has limited drug-drug interactions. Most co-administered drugs are safe, with a dose adjustment needed only for rifampin.
Area of Science:
- Pharmacology
- Infectious Diseases
- Drug Interactions
Background:
- Raltegravir is a key component in HIV treatment regimens.
- Understanding its drug-drug interaction profile is crucial for safe and effective patient management.
Purpose of the Study:
- To comprehensively review all published drug-drug interaction studies involving the HIV-integrase inhibitor raltegravir.
- To consolidate current knowledge on raltegravir's interactions with other medications.
Main Methods:
- Conducted a systematic PubMed search for relevant studies up to August 1, 2009.
- Reviewed updated European (EMEA) and US (FDA) Prescriber's Information.
- Included abstracts from recent international scientific meetings to ensure comprehensive data capture.
Main Results:
- Identified 14 drug-drug interaction studies concerning raltegravir.
- Raltegravir exhibits a broad therapeutic range, allowing safe co-administration with most agents.
- An exception is rifampin, for which a raltegravir dose increase to 800 mg twice daily is recommended.
Conclusions:
- Raltegravir does not significantly impact CYP450 or UGT enzymes, contributing to its favorable interaction profile.
- The drug's broad therapeutic index facilitates safe combination therapy with a wide array of medications.
- Raltegravir can be safely combined with most tested agents, simplifying treatment regimens.
More Related Videos
Related Concept Videos
01:25Pharmacokinetics: Drug–Drug Interactions
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
01:26Pharmacokinetics: Drug–Food and Drug–Viral Interactions
A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of many...
01:30Drug toxicity: Drug–Drug Interaction
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:24Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
01:23Factors Affecting Protein-Drug Binding: Drug Interactions
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...